Publications by authors named "Tamika Magee"
Article Synopsis
- - Hypereosinophilic syndrome is characterized by high eosinophil levels in blood or tissue, leading to various health issues, and benralizumab is a targeted therapy that blocks a receptor on eosinophils.
- - In a phase 2 clinical trial, patients received either benralizumab or a placebo, with the main goal being a significant reduction in eosinophil counts after 12 weeks; results showed a much higher response rate in the benralizumab group (90% vs. 30%).
- - The treatment not only led to sustained improvements in about 74% of patients but also allowed some to reduce their other medications; however, around 32% experienced mild side effects like headaches
